Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH-Reference-Cited by-同舟云学术

Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH

Published:2020-07 Issue:1 Volume:73 Page:17-25
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Ampuero Javier,Aller Rocío,Gallego-Durán Rocío,Crespo Javier,Calleja José Luis,García-Monzón Carmelo,Gómez-Camarero Judith,Caballería Joan,Lo Iacono Oreste,Ibañez Luis,García-Samaniego Javier,Albillos Agustín,Francés Rubén,Fernández-Rodríguez Conrado,Diago Moisés,Soriano Germán,Andrade Raúl J.,Latorre Raquel,Jorquera Francisco,Morillas Rosa María,Escudero Desamparados,Estévez Pamela,Guerra Manuel Hernández,Augustín Salvador,Banales Jesús M.,Aspichueta Patricia,Benlloch Salvador,Rosales José Miguel,Salmerón Javier,Turnes Juan,Romero Gómez Manuel

Funder

Consejería de Salud de la Junta de Andalucía

Instituto de Salud Carlos III

Publisher

Elsevier BV

Subject

Hepatology

Reference34 articles.

1. Past, present and future perspectives in nonalcoholic fatty liver disease;Sanyal;Nat Rev Gastroenterol Hepatol,2019

2. Fatty liver: a novel component of the metabolic syndrome;Kotronen;Arterioscler Thromb Vasc Biol,2008

3. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity;Ampuero;Aliment Pharmacol Ther,2018

4. Is nonalcoholic fatty liver disease the hepatic expression of the metabolic syndrome?;Yilmaz;World J Hepatol,2012

5. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome;Lonardo;Dig Liver Dis,2015

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ammonia-induced stress response in liver disease progression and hepatic encephalopathy;Nature Reviews Gastroenterology & Hepatology;2024-09-09

2. Phenotypes of Metabolic Dysfunction–Associated Steatotic Liver Disease–Associated Hepatocellular Carcinoma;Clinical Gastroenterology and Hepatology;2024-09

3. One‐step non‐invasive diagnosis of metabolic dysfunction‐associated steatohepatitis and fibrosis in high‐risk population;United European Gastroenterology Journal;2024-08-04

4. Needs assessment for creation of a platform trial network in metabolic-dysfunction associated steatohepatitis;Communications Medicine;2024-07-16

5. Fibroblast growth factor 21 is a hepatokine involved in MASLD progression;United European Gastroenterology Journal;2024-06-18